迪亚泽帕姆结合抑制剂 控制中风中介性下丘脑核葡萄糖调节信号的eu和低血糖模式
Sagor C Roy1, Subash Sapkota1, Madhu Babu Pasula1
1School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA, USA.
ASN neuro
|November 30, 2023
概括
低血糖差异性影响在中腹下垂体 (VMN) 中的八十二烯 (ODN) 信号传递. 在正常和低葡萄糖条件下,ODN信号独特地控制在VMN的不同区域中的调节葡萄糖的神经递质.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 星球细胞衍生性八十甲基 (ODN) 信号影响着下丘脑神经传递.
- 下丘脑的中腹核 (VMN) 在葡萄糖平衡中起着至关重要的作用.
- 了解ODN在代谢挑战期间VMN神经递质调节中的作用至关重要.
研究的目的:
- 调查低血糖对VMNODN内容的影响.
- 为了确定ODN信号是否调节GABA和氧化物在eU和低血糖期间在VMN中传播.
- 探索VMN内部关于ODN监管效应的区域差异.
主要方法:
- 毛细管区电泳-质谱仪的开发,用于脑组织中的ODN量化.
- 在VMN中利用基因淘汰 (siRNA) 向泽结合抑制剂 (ODN的前体).
- 激光微解剖和分析特定的神经元群体 (GABAergic,nitrergic) 和基因表达 (GAD,glucokinase,AMPK).
主要成果:
- 低血糖诱导了ODN前体和ODN水平在背中 (DM) 与腹侧 (VL) VMN的明显变化.
- 在低血糖症期间,泽结合抑制剂的淘汰改变了GABAergic和nitrergic神经元基因表达,具有特定区域的影响.
- 在不同的葡萄糖条件下,ODN信号在VMN子区域的差异调制葡萄糖激酶和AMPK转录.
结论:
- 毛细管区电泳-质谱是有效的量化ODN在小的大脑样本.
- 低血糖对VMN的神经解剖学部门内的ODN信号产生差异性影响.
- 在正常和低血糖状态下,ODN信号对VMNdm和VMNvl中的葡萄糖调节神经传递施加明显的控制.
关键词:
迪亚泽帕姆结合抑制剂QTRAP CESI-MS/MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QTRAP CESI-MS/QM谷氨酸脱碳酶酶酶是一种谷氨酸脱碳酶酶酶.胰岛素诱导的低血糖症性别差异的性别差异.siRNA基因被淘汰的情况相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209


